October 30, 2020 Conference

  


TEST
Title
Severe Nonproliferative Diabetic Retinopathy: What To Do Now?


Author
Dr. Brian Y. Kim, University of Vermont Medical Center (Presenter)
Abstract

Diabetic retinopathy continues to be a leading cause of blindness worldwide. Duration of disease as well as severity of hyperglycemia are among the factors known to be major risks for both the development and progression of diabetic retinopathy. Proliferative diabetic retinopathy has been identified as the most vision threatening form of the disease. Thus, treatment of the nonproliferative stages of the disease remains important. Specifically focusing on severe nonproliferative disease, progression to proliferative disease is very high, with over 50% of patients progressing to proliferative disease within one year. Classic trials such as the Diabetic Retinopathy Study, as well as the Early Treatment Diabetic Retinopathy Study have given guidance for treatment options for these patients. Newer trials such as PANORAMA also specifically look at the use of anti-VEGF therapy for patients with severe nonproliferative diabetic retinopathy. We will review those results in this session.

Presentation Video